Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-year durability of glycemic control: vildagliptin + metformin vs metformin monotherapy in treatment-naive type 2 diabetes
2011-003712-23Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin + metformin combination therapy with Metformin monotherapy (2 arms). Primary endpoint: HbA1c measurement. Started Nov 2011; status: completed.
02
Drugs
vildagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-003712-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003712-23.